Inherited Thrombophilias in Pregnancy
Publication Date: June 30, 2018
Last Updated: March 14, 2022
Summary of Recommendations
The following recommendations are based on limited or inconsistent scientific evidence.
- Screening for inherited thrombophilias is not recommended for women with a history of fetal loss or adverse pregnancy outcomes including abruption, preeclampsia, or fetal growth restriction because there is insufficient clinical evidence that ante-partum prophylaxis with unfractionated heparin or low-molecular-weight heparin prevents recurrence in these patients.
- Because of the lack of association between either heterozygosity or homozygosity for the MTHFR C677T polymorphism and any negative pregnancy outcomes, including any increased risk of VTE, screening with either MTHFR mutation analyses or fasting homocysteine levels is not recommended.
- Warfarin, low-molecular-weight heparin, and un-fractionated heparin do not accumulate in breast milk and do not induce an anticoagulant effect in the infant. Therefore, these anticoagulants may be used in women who breastfeed.
( B )574
Title
Inherited Thrombophilias in Pregnancy
Authoring Organization
American College of Obstetricians and Gynecologists